Stefan Grant to Treatment Outcome
This is a "connection" page, showing publications Stefan Grant has written about Treatment Outcome.
Connection Strength
0.041
-
Hong DS, Moore K, Patel M, Grant SC, Burris HA, William WN, Jones S, Meric-Bernstam F, Infante J, Golden L, Zhang W, Martinez R, Wijayawardana S, Beckmann R, Lin AB, Eng C, Bendell J. Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. Clin Cancer Res. 2018 07 15; 24(14):3263-3272.
Score: 0.022
-
Allendorf DJ, Bordoni RE, Grant SC, Saleh MN, Reddy VB, Jerome ML, Dixon PM, Miley DK, Singh KP, Robert F. Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC). Cancer Chemother Pharmacol. 2015 Nov; 76(5):949-55.
Score: 0.019